According to Zacks, “Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company?s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. “
CNTG has been the topic of a number of other research reports. BTIG Research boosted their price objective on Centogene from $18.00 to $23.00 and gave the stock a buy rating in a research note on Friday, April 24th. Robert W. Baird upped their price target on Centogene from $15.00 to $20.00 and gave the company an outperform rating in a research note on Friday, April 24th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $20.00.
Centogene (NASDAQ:CNTG) last released its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.10). The firm had revenue of $13.35 million during the quarter, compared to analyst estimates of $13.78 million. As a group, equities analysts expect that Centogene will post -1.74 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Centogene by 1,055.3% during the first quarter. Wells Fargo & Company MN now owns 1,756 shares of the company’s stock valued at $35,000 after acquiring an additional 1,604 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Centogene by 23.7% during the first quarter. JPMorgan Chase & Co. now owns 3,054 shares of the company’s stock valued at $61,000 after acquiring an additional 586 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Centogene during the first quarter valued at $67,000. UBS Group AG acquired a new position in Centogene in the fourth quarter valued at about $38,000. Finally, New York State Common Retirement Fund acquired a new position in Centogene in the fourth quarter valued at about $97,000. 8.35% of the stock is currently owned by institutional investors and hedge funds.
Centogene Company Profile
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Recommended Story: What is a good dividend yield?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.